About 15,430 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,830 results

Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: A pilot prospectiv...
International Journal of Rheumatic Diseases; Ak T, Temiz SNY et. al.

Mar 18th, 2023 - This study aimed to show the effectiveness of interleukin (IL)-23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real-world setting. Forty-three patients with active PsA were enrolled in this study. These patients were treated wit...

Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclero...
Autoimmunity Reviews; Konen FF, Möhn N et. al.

Mar 17th, 2023 - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to di...

Thrombocytosis in patients with spondyloarthritis: a case-control study.
BMC Musculoskeletal Disorders; Deng L, Zheng P

Mar 17th, 2023 - This study aimed to investigate the clinical and laboratory as well as radiological features of spondyloarthritis (SpA) patients with thrombocytosis and to explore risk factor for thrombocytosis in SpA patients and to assess the effect of antitumo...

Site-specific assessment of spinal radiographic progression improves detection of TNF b...
Arthritis Research & Therapy; Popova V, Kissling S et. al.

Mar 15th, 2023 - To analyse whether time-varying treatment with tumour necrosis factor inhibitors (TNFi) in radiographic axial spondyloarthritis (r-axSpA) has a differential impact on structural damage progression on different spinal segments (cervical versus lumb...

Responsiveness and minimal clinically important difference in patient-reported outcome ...
Arthritis Care & Research; Karmacharya P, Stull C et. al.

Mar 14th, 2023 - To determine the responsiveness to therapy and minimally clinically important improvement (MCII) for patient-reported outcome (PRO) measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demo...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  1,077 results see all →

Clinicaltrials.gov  392 results

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Mar 9th, 2023 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment...

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Mar 9th, 2023 - This was a Phase IIIb, multi-center, randomized, partially-blinded, active-controlled, parallel-group design in subjects with AS. The study consisted of a screening period (up to 10 weeks before randomization), a treatment period (104 weeks), and ...

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyl...

Mar 8th, 2023 - The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and...

Awareness of Osteoporosis in Ankylosing Spondylosis Patients

Mar 8th, 2023 - Osteoporosis is a common disease of bone loss. The reduced bone strength predisposes an increased risk for fractures in older individuals. It can affect people from different ethnicity. Many factors increase the risk of osteoporosis, including age...

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Mar 7th, 2023 - This study includes two periods: a 14-week double-blind placebo-controlled period and a 90-week open-label long-term extension period. Eligible participants were randomly assigned in a 1:1 ratio to receive upadacitinib 15 mg or placebo for 14 week...

see more →

News  835 results

Commentary: Concerning PsA treatments and comorbidities, March 2023
Vinod Chandran, MBBS, MD, DM, PhD

Mar 1st, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Psoriatic arthritis (PsA) is a heterogeneous disease with clinical manifestations affecting the skin, joints, spine, and periarticular structures, such as the entheses and tendons. The impact of these manifestatio.

Taltz Safety, Efficacy Stay Robust in Spondyloarthritis at 3 Years

Feb 21st, 2023 - Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who continued on the drug for 3 years, without any ...

Long-term safety and tolerability of upadacitinib in PsA

Feb 14th, 2023 - Key clinical point: Upadacitinib demonstrated an acceptable long-term safety profile and was generally well tolerated with no new safety signals in patients with psoriatic arthritis (PsA). Major finding: Overall, patients with PsA receiving 15 mg.

PsA-related uveitis: Real-world data on epidemiology and clinical features

Jan 26th, 2023 - Key clinical point: Uveitis related to psoriatic arthritis (PsA) had a prevalence of approximately 5%, presented as an acute and recurrent disease with anterior and unilateral involvement, and was associated with impaired quality of life and incre.

TNFi raises the risk for septic arthritis in seropositive RA

Jan 24th, 2023 - Key clinical point: Tumor necrosis factor inhibitors (TNFi) increased the risk for septic arthritis in patients with seropositive rheumatoid arthritis (RA), with higher incidences within 1 year of initiating TNFi. Major finding: Patients with sero.

see more →

Patient Education  27 results see all →